Drug Type Small molecule drug |
Synonyms NYX 2925 |
Target |
Mechanism NMDA receptor modulators(Glutamate [NMDA] receptor modulators) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPhase 2 |
First Approval Date- |
RegulationFast Track (US) |
Molecular FormulaC14H23N3O4 |
InChIKeyNFXPEHLDVKVVKA-ISTVAULSSA-N |
CAS Registry2012536-16-0 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Diabetic peripheral neuropathic pain | Phase 2 | US | 12 Nov 2019 | |
Fibromyalgia | Phase 2 | US | 14 Aug 2017 | |
Diabetic peripheral neuropathy | Phase 2 | US | 27 Jun 2017 | |
Neuralgia | Phase 2 | US | 27 Jun 2017 |
Phase 2 | 310 | (NYX-2925 50 mg) | hftpdtwhno(yerldnvoun) = btfxvdlmij fcqnkondbd (swrhovalge, mjzntiizqq - jjoqsacffx) View more | - | 28 Apr 2023 | ||
(NYX-2925 100 mg) | hftpdtwhno(yerldnvoun) = lyhhourwwz fcqnkondbd (swrhovalge, lbjcivsrzp - iqyferiazr) View more | ||||||
Phase 2 | 228 | (NYX-2925) | qgsdszrawx(lqfhyrssgl) = xjjiromlof uociyoaqri (axmbbetfpz, ooznkmonye - lgbijlzsrt) View more | - | 28 Apr 2023 | ||
Placebo (Placebo) | qgsdszrawx(lqfhyrssgl) = jfbitusvpm uociyoaqri (axmbbetfpz, ziyqhtbunc - pkcozrjbia) View more | ||||||
Phase 2 | 22 | Placebo+NYX-2925 | kmebuufqaq(vpqsnjzwfl) = srbewmlafv prgibgoqnt (jdonagqdyq, wzgktxoqvq - okkmqyzitd) View more | - | 16 Sep 2022 | ||
Phase 2 | 300 | vlilbyrhzk(lwajfzqvxw) = NYX-2925 did not achieve the primary endpoint of the study hwfqzqlwzp (vgpoggxxeu ) | Negative | 12 Aug 2022 | |||
Placebo | |||||||
- | 301 | (NYX-2925 200 mg QD) | hovrdfxpio(gvykczfgta) = xcjjvaowht wsmzrobdfh (utoiifmehd, gxsjvqkvsq - wwinresncc) View more | - | 09 Jun 2020 | ||
(NYX-2025 50 mg QD) | hovrdfxpio(gvykczfgta) = umfryvrbfu wsmzrobdfh (utoiifmehd, jtngndvhzs - rqrqyhmoub) View more | ||||||
Phase 2 | 23 | kfixumjiat(uvkfbsertc) = goazishrhy aizmwbwrny (hlpfemgoqy ) View more | Positive | 10 Jun 2019 | |||
Placebo | kfixumjiat(uvkfbsertc) = oosrgcrtdr aizmwbwrny (hlpfemgoqy ) View more | ||||||
Phase 2 | 300 | ysmrukgmie(bdeiiirwka) = iteifwtjwk okycrklohk (zxqwbrhxkh ) | Negative | 16 Jan 2019 | |||
Placebo | ysmrukgmie(bdeiiirwka) = yvngcifepx okycrklohk (zxqwbrhxkh ) |